{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:23:34Z","timestamp":1793147014832,"version":"4.5.0"},"reference-count":58,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"DOI":"10.1001\/jamasurg.2021.0891","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T08:01:46Z","timestamp":1619078506000},"page":"e210891","source":"Crossref","is-referenced-by-count":210,"title":["Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease"],"prefix":"10.1001","volume":"156","author":[{"given":"Sanaz","family":"Samiei","sequence":"first","affiliation":[{"name":"Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"GROW\u2013School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine M.","family":"Simons","sequence":"additional","affiliation":[{"name":"GROW\u2013School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne M. E.","family":"Engelen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina G. H.","family":"Beets-Tan","sequence":"additional","affiliation":[{"name":"GROW\u2013School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands"},{"name":"Department of Radiology, the Netherlands Cancer Institute, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Classe","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Institut de Canc\u00e9rologie de l\u2019Ouest, Saint-Herblain, Loire Atlantique, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[{"name":"Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"GROW\u2013School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EUBREAST Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"issue":"9938","key":"soi210016r1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"soi210016r2","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"issue":"18","key":"soi210016r3","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"issue":"36","key":"soi210016r4","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","article-title":"Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.","volume":"23","author":"Hennessy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"soi210016r5","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","article-title":"Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.","volume":"20","author":"Rouzier","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"soi210016r6","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/cncr.v116:12","article-title":"Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.","volume":"116","author":"Dominici","year":"2010","journal-title":"Cancer"},{"issue":"10","key":"soi210016r7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection.","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"soi210016r8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clbc.2017.04.006","article-title":"A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the axilla with the sentinel node procedure (RISAS): a Dutch prospective multicenter validation study.","volume":"17","author":"van Nijnatten","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"soi210016r9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"issue":"7","key":"soi210016r10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.ejso.2016.03.023","article-title":"Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: a nationwide survey study in the Netherlands.","volume":"42","author":"Vugts","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"soi210016r11","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-017-5958-4","article-title":"Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of American Society of Breast Surgeons Members.","volume":"24","author":"Caudle","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"soi210016r12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ejso.2015.07.020","article-title":"The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review and meta-analysis.","volume":"41","author":"van Nijnatten","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"soi210016r13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: the PRISMA-DTA statement.","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"soi210016r14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a STATA command to perform meta-analysis of binomial data.","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"issue":"11","key":"soi210016r15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"5","key":"soi210016r16","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/tbj.v26.5","article-title":"Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.","volume":"26","author":"Fernandez-Gonzalez","year":"2020","journal-title":"Breast J"},{"issue":"4","key":"soi210016r17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","article-title":"Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy.","volume":"2","author":"Mougalian","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"soi210016r18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB).","volume":"268","author":"Fayanju","year":"2018","journal-title":"Ann Surg"},{"issue":"1","key":"soi210016r19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10549-017-4157-0","article-title":"Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.","volume":"163","author":"van Nijnatten","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"soi210016r20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40644-019-0279-4","article-title":"Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer.","volume":"19","author":"Al-Hattali","year":"2019","journal-title":"Cancer Imaging"},{"issue":"3","key":"soi210016r21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12282-018-00934-3","article-title":"Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.","volume":"26","author":"Bi","year":"2019","journal-title":"Breast Cancer"},{"issue":"4","key":"soi210016r22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/SLA.0000000000002373","article-title":"Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance).","volume":"266","author":"Boughey","year":"2017","journal-title":"Ann Surg"},{"issue":"2","key":"soi210016r23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/tbj.2019.25.issue-2","article-title":"Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: are we ready to endorse axillary conservation?","volume":"25","author":"Cerbelli","year":"2019","journal-title":"Breast J"},{"issue":"3","key":"soi210016r24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-019-05214-y","article-title":"Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy.","volume":"176","author":"Choi","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"soi210016r25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.clbc.2016.02.009","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of cytology-proven lymph node-positive breast cancer.","volume":"16","author":"Enokido","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"13","key":"soi210016r26","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1245\/s10434-019-07915-6","article-title":"Heterogeneous responses of axillary lymph node metastases to neoadjuvant chemotherapy are common and depend on breast cancer subtype.","volume":"26","author":"Glaeser","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"soi210016r27","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1245\/s10434-018-6613-4","article-title":"Predicting post neoadjuvant axillary response using a novel convolutional neural network algorithm.","volume":"25","author":"Ha","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"soi210016r28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4048\/jbc.2019.22.e35","article-title":"Potential benefits of neoadjuvant chemotherapy in clinically node-positive luminal subtype-breast cancer.","volume":"22","author":"Kim","year":"2019","journal-title":"J Breast Cancer"},{"issue":"43","key":"soi210016r29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001720","article-title":"Prognostic nomogram for prediction of axillary pathologic complete response after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.","volume":"94","author":"Kim","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"soi210016r30","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1245\/s10434-013-2902-0","article-title":"Early assessment of axillary response with 18F-FDG PET\/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.","volume":"20","author":"Koolen","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"soi210016r31","article-title":"ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"soi210016r32","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.clbc.2016.06.020","article-title":"Feasibility and prognostic effect of sentinel lymph node biopsy after neoadjuvant chemotherapy in cytology-proven, node-positive breast cancer.","volume":"17","author":"Park","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"soi210016r33","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1245\/s10434-013-2992-8","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.","volume":"20","author":"Park","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"soi210016r34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.amjsurg.2017.11.015","article-title":"Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment.","volume":"215","author":"Qu","year":"2018","journal-title":"Am J Surg"},{"key":"soi210016r35","first-page":"S72","article-title":"Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy.","volume":"26","author":"Samiei","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"soi210016r36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clbc.2013.12.015","article-title":"A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.","volume":"14","author":"Schipper","year":"2014","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"soi210016r37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery.","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"},{"key":"soi210016r38","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S0960-9776(19)30253-X","article-title":"Subtype-guided 18F-FDG PET\/CT in tailoring axillary surgery among node-positive breast cancer patients treated with neoadjuvant chemotherapy: a feasibility study.","volume":"44","author":"Wu","year":"2019","journal-title":"Breast"},{"issue":"6","key":"soi210016r39","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ejso.2019.01.219","article-title":"Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: time trend, imaging staging power and nodal downstaging according to molecular subtype.","volume":"45","author":"Di Micco","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"soi210016r40","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1245\/s10434-017-6085-y","article-title":"Tumor biology predicts pathologic complete response to neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer.","volume":"24","author":"Gentile","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"soi210016r41","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1245\/s10434-018-6345-5","article-title":"A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer.","volume":"25","author":"Kantor","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"soi210016r42","article-title":"Impact of the extent of pathologic complete response on outcomes after neoadjuvant chemotherapy.","author":"Lee","journal-title":"J Surg Oncol"},{"issue":"2","key":"soi210016r43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.suronc.2018.02.003","article-title":"Risk scoring system for predicting axillary response after neoadjuvant chemotherapy in initially node-positive women with breast cancer.","volume":"27","author":"Ouldamer","year":"2018","journal-title":"Surg Oncol"},{"issue":"9","key":"soi210016r44","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1245\/s10434-017-5898-z","article-title":"Standard pathologic features can be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy.","volume":"24","author":"Petruolo","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"soi210016r45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000489785","article-title":"Predictors of pathological complete response in women with clinical complete response to neoadjuvant chemotherapy in breast carcinoma.","volume":"95","author":"Resende","year":"2018","journal-title":"Oncology"},{"issue":"1","key":"soi210016r46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jss.2016.04.048","article-title":"Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.","volume":"204","author":"Steiman","year":"2016","journal-title":"J Surg Res"},{"issue":"11","key":"soi210016r47","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1245\/s10434-019-07583-6","article-title":"Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a National Cancer Database analysis.","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"soi210016r48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"soi210016r49","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"soi210016r50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"soi210016r51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","article-title":"Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis.","volume":"269","author":"Simons","year":"2019","journal-title":"Ann Surg"},{"issue":"2","key":"soi210016r52","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-017-6263-y","article-title":"Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype.","volume":"25","author":"Al-Hilli","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"soi210016r53","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-020-05589-3","article-title":"De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.","volume":"180","author":"Simons","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"soi210016r54","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1245\/s10434-018-6637-9","article-title":"Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy.","volume":"25","author":"Nguyen","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"soi210016r55","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"soi210016r56","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy.","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"soi210016r57","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.","volume":"95","author":"Fisher","year":"2002","journal-title":"Cancer"},{"issue":"11","key":"soi210016r58","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","article-title":"Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer.","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2778930\/jamasurgery_samiei_2021_oi_210016_1622842071.31906.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T11:31:01Z","timestamp":1623238261000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2778930"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2021.0891","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,9]]}}}